Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CEP-701; KT 5555; SPM 924

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Cephalon; Children's Oncology Group; Icahn School of Medicine at Mount Sinai; Kyowa Hakko; National Cancer Institute (USA); Teva Pharmaceutical Industries
  • Class Antineoplastics; Carbazoles; Indoles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Discontinued Multiple myeloma; Pancreatic cancer; Plaque psoriasis; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Jan 2018 Lestaurtinib is still in phase III trials for Acute lymphoblastic leukaemia (Combination therapy, In infants, Newly diagnosed) in USA, New Zealand, Canada and Australia (PO) (NCT00557193)
  • 04 Sep 2015 Phase-II development for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy), Myelofibrosis, Polycythaemia vera and Thrombocytosis is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top